Vikram Purohit
Stock Analyst at Morgan Stanley
(1.87)
# 3,332
Out of 5,182 analysts
163
Total ratings
34.85%
Success rate
-7.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Maintains: Overweight | $18 → $16 | $8.75 | +82.86% | 4 | Mar 25, 2026 | |
| INCY Incyte | Maintains: Equal-Weight | $92 → $94 | $96.74 | -2.83% | 26 | Jan 6, 2026 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $31 → $34 | $20.07 | +69.41% | 3 | Oct 28, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $80 → $79 | $68.40 | +15.50% | 11 | Oct 20, 2025 | |
| ABSI Absci | Maintains: Overweight | $6.4 → $5.89 | $3.68 | +60.05% | 3 | Aug 18, 2025 | |
| RXRX Recursion Pharmaceuticals | Assumes: Equal-Weight | $5 | $3.73 | +34.05% | 4 | Jul 3, 2025 | |
| ASND Ascendis Pharma | Upgrades: Overweight | $180 → $250 | $231.05 | +8.20% | 19 | May 5, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $125 → $190 | $186.42 | +1.92% | 19 | Feb 27, 2025 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $5.39 | +66.98% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $27.69 | +11.95% | 2 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $16 | $115.99 | -86.21% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $23.75 | -57.89% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $9.34 | +349.68% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $88.77 | -53.81% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $8.41 | +375.62% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $2.09 | +522.01% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $12.35 | +207.69% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $6.38 | +213.48% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $16.57 | -39.65% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.25 | +1,660.00% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $19.76 | +1.21% | 2 | Aug 5, 2020 |
COMPASS Pathways
Mar 25, 2026
Maintains: Overweight
Price Target: $18 → $16
Current: $8.75
Upside: +82.86%
Incyte
Jan 6, 2026
Maintains: Equal-Weight
Price Target: $92 → $94
Current: $96.74
Upside: -2.83%
Zenas BioPharma
Oct 28, 2025
Maintains: Overweight
Price Target: $31 → $34
Current: $20.07
Upside: +69.41%
Halozyme Therapeutics
Oct 20, 2025
Maintains: Overweight
Price Target: $80 → $79
Current: $68.40
Upside: +15.50%
Absci
Aug 18, 2025
Maintains: Overweight
Price Target: $6.4 → $5.89
Current: $3.68
Upside: +60.05%
Recursion Pharmaceuticals
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $5
Current: $3.73
Upside: +34.05%
Ascendis Pharma
May 5, 2025
Upgrades: Overweight
Price Target: $180 → $250
Current: $231.05
Upside: +8.20%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125 → $190
Current: $186.42
Upside: +1.92%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $5.39
Upside: +66.98%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $27.69
Upside: +11.95%
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $115.99
Upside: -86.21%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $23.75
Upside: -57.89%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $9.34
Upside: +349.68%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $88.77
Upside: -53.81%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $8.41
Upside: +375.62%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $2.09
Upside: +522.01%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $12.35
Upside: +207.69%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $6.38
Upside: +213.48%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $16.57
Upside: -39.65%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $1.25
Upside: +1,660.00%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $19.76
Upside: +1.21%